Epidemiologic, clinical, and virologic features of the 102 HCV antibody–positive hemophiliacs
Features . | HCV antibody–positive hemophiliacs (n = 102) . |
---|---|
Median age, y (range) | 45.1 (15-71) |
Median age at infection, y (range) | 20.1 (1-56) |
Median duration of infection, y (range) | 25.1 (15-34) |
Sex | |
Male | 88 (86.3)* |
Female | 14 (13.7)* |
Diagnosis | |
Mild/moderate hemophilia | 48 (47.1)* |
Severe hemophilia | 34 (33.3)* |
von Willebrand disease | 20 (19.6)* |
HCV genotype† | |
1a | 18 (20.5)* |
1b | 32 (36.4)* |
2 | 15 (17.0)* |
3 | 14 (15.9)* |
4 | 3 (3.4)* |
1a + 1b | 5 (5.7)* |
1a + 2 | 1 (1.1)* |
Liver status | |
Normal ALT levels‡ | 29 (28.4)* |
Chronic hepatitis | 61 (59.8)* |
Liver cirrhosis | 6 (5.9)* |
Hepatic decompensation | 4 (3.9)* |
Hepatocellular carcinoma | 2 (2.0)* |
Features . | HCV antibody–positive hemophiliacs (n = 102) . |
---|---|
Median age, y (range) | 45.1 (15-71) |
Median age at infection, y (range) | 20.1 (1-56) |
Median duration of infection, y (range) | 25.1 (15-34) |
Sex | |
Male | 88 (86.3)* |
Female | 14 (13.7)* |
Diagnosis | |
Mild/moderate hemophilia | 48 (47.1)* |
Severe hemophilia | 34 (33.3)* |
von Willebrand disease | 20 (19.6)* |
HCV genotype† | |
1a | 18 (20.5)* |
1b | 32 (36.4)* |
2 | 15 (17.0)* |
3 | 14 (15.9)* |
4 | 3 (3.4)* |
1a + 1b | 5 (5.7)* |
1a + 2 | 1 (1.1)* |
Liver status | |
Normal ALT levels‡ | 29 (28.4)* |
Chronic hepatitis | 61 (59.8)* |
Liver cirrhosis | 6 (5.9)* |
Hepatic decompensation | 4 (3.9)* |
Hepatocellular carcinoma | 2 (2.0)* |